# A. Jo Chien

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/a-jo-chien/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,708 |
| Field | Breast Cancer Treatment Studies |
| h-index | 39 |
| i10-index | 81 |
| Last Known Institution | University of California, San Francisco |
| OpenAlex ID | https://openalex.org/A5053577410 |
| ORCID iD | 0000-0003-2978-6249 |
| Works | 210 |

## Researcher papers

- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)
- [Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer](https://scholariq.org/papers/pretreatment-fertility-counseling-and-fertility-preservation-improve-quality-of/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial](https://scholariq.org/papers/intracranial-efficacy-and-survival-with-tucatinib-plus-trastuzumab-and/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival](https://scholariq.org/papers/circulating-tumor-dna-in-neoadjuvant-treated-breast-cancer-reflects-response-and/)
- [w4200350191](https://scholariq.org/papers/w4200350191/)
- [Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial](https://scholariq.org/papers/durvalumab-with-olaparib-and-paclitaxel-for-high-risk-her2-negative-stage-ii-iii/)
- [Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](https://scholariq.org/papers/association-of-event-free-and-distant-recurrence-free-survival-with-individual/)
- [The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB)](https://scholariq.org/papers/the-impact-of-histologic-subtype-on-primary-site-surgery-in-the-management-of/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [University of California, San Francisco](https://scholariq.org/institutions/university-of-california-san-francisco/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.